Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1. (2021)

• Record Type: Journal Article
• Authors: Takeuchi, Asako; Kondo, Toshinori; Tasaka, Taizo; Yamada, Seiko; Hirose, Tadashi; Fukuda, Hirofumi; Shimizu, Risa; Matsuhashi, Yoshiko; Kondo, Eisei; Wada, Hideho
• Is Part Of: Leukemia research reports. Volume 15(2021)
• Publication Date: 2021
• Subjects: Acute myeloid leukemia -- BCR-ABL1 -- Philadelphia chromosome -- Tyrosine kinase inhibitor; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2020.100233
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with dasatinib alone; additionally, we previously reported another case of long-term remission maintained with imatinib monotherapy. These results suggested that a treatment with a novel and significantly potent TKI may be effective in AML with BCR-ABL1 patients with low tumor burden and without additional chromosome aberrations and ABL kinase domain mutations.